<div id="readability-page-1"><div>Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The &#34;Weight Loss Drugs Market - A Global and Regional Analysis: Focus on Type, Mechanism of Action, Route of Administration, Distribution Channel, and Country-Level Analysis - Analysis and Forecast, 2025-2035&#34; report has been added to ResearchAndMarkets.com's offering.The weight loss drugs market has experienced significant growth in recent years, largely driven by the increasing global prevalence of obesity and related health conditions. As more individuals seek effective and convenient solutions for managing their weight, the pharmaceutical industry has responded by offering a variety of drug options designed to aid in weight loss or help maintain a healthy weight.</div> <div>According to the World Health Organization (WHO), over 2 billion people worldwide were classified as overweight or obese in 2021. This growing health concern has made weight loss drugs an attractive solution for individuals who struggle to lose weight through traditional methods such as diet and exercise. Additionally, obesity is linked to several chronic diseases, including type 2 diabetes, cardiovascular diseases, and certain cancers, further driving the demand for effective weight loss treatments.Furthermore, advances in medical research have led to the development of more effective and safer weight loss medications, thereby driving the market growth. For instance, semaglutide (Wegovy) has shown promise in clinical trials, with patients losing up to 15% of their body weight after a year of treatment. This has created a wave of interest in prescription medications that go beyond the limitations of traditional diet pills. Also, the emergence of injectable drugs such as Wegovy and Saxenda has provided alternative options for individuals who cannot rely on oral medications. This is expected to impel the market growth over a forecast period.However, side effects and safety concerns related to weight loss drugs are expected to limit the adoption and hinder market growth. Some medications such as orlistat can lead to gastrointestinal issues, while others may cause mood swings or increase the risk of heart-related problems. Consumers are often cautious about taking medications that come with potential long-term health risks. Even newer drugs like semaglutide, which show promising results, can lead to side effects such as nausea, vomiting, and diarrhea, which may deter individuals from continued use.In addition, the high cost of prescription weight loss medications can be a major barrier to access, especially in countries with less favorable insurance coverage or where individuals do not have the financial means to afford treatment.Key players in the market are Eli Lilly &amp; Co, Pfizer Inc., F. Hoffmann-La Roche, GlaxoSmithKline (GSK), Sun Pharma, Amgen Inc., Rhythm Pharmaceuticals, Currax Holdings USA LLC, Boehringer Ingelheim, Vivus Inc., Gelesis, and Novo Nordisk</div> <div>Prescription Weightloss Drug to Lead the Weight Loss Drug MarketPrescription weight loss drugs dominate the market over OTC alternatives due to their superior efficacy, strong clinical validation, and the ability to be closely monitored by healthcare providers. Medications like Wegovy (semaglutide) and Saxenda (liraglutide) have demonstrated significant weight loss results in clinical trials, targeting key metabolic pathways such as appetite control and fat metabolism. These FDA-approved drugs are often prescribed to individuals with obesity or related comorbidities, providing a personalized, evidence-based treatment approach.</div> <div>In contrast, OTC options such as Alli (orlistat) offer limited effectiveness and lack the rigorous regulatory oversight and clinical backing that prescription drugs benefit from. The success of prescription drugs like Ozempic, initially developed for diabetes, further solidifies their dominance, as they provide weight loss of up to 20% of body weight, which is a more attractive and reliable proposition compared to the modest results typically associated with OTC products.North America Region to Lead the Weight Loss MarketNorth America is dominating the weight loss drug market due to a combination of high obesity rates, strong healthcare infrastructure, and significant investment in pharmaceutical innovation. In the U.S., nearly 42% of adults are obese, according to the CDC, which drives a growing demand for weight loss solutions. Pharmaceutical companies have capitalized on this demand, with drugs such as Wegovy and Ozempic gaining massive popularity.</div> These medications, originally developed for diabetes, have shown remarkable success in promoting weight loss and are now marketed as primary solutions for obesity. The U.S. also has one of the highest rates of medical prescriptions for weight management, supported by insurance reimbursements and widespread access to healthcare. This has created a favorable environment for companies to aggressively market these treatments, thus maintaining North America's lead in the global weight loss drug market. Weight Loss Drugs Market Competitive Landscape <ul><li>Novo Nordisk</li><li>Eli Lilly &amp; Co</li><li>Pfizer Inc.</li><li>F. Hoffmann-La Roche</li><li>GlaxoSmithKline (GSK)</li><li>Sun Pharma</li><li>Amgen Inc.</li><li>Rhythm Pharmaceuticals</li><li>Currax Holdings USA LLC</li><li>Boehringer Ingelheim</li><li>Vivus Inc.</li><li>Gelesis</li></ul> <div>Key Topics Covered:Executive Summary 1. Product Definition 1.1 Inclusion and Exclusion2. Market Scope 2.1 Scope of Work 2.2 Key Questions Answered in the Report3. Research Methodology 3.1 Data Sources 3.1.1 Primary Data Sources 3.1.2 Secondary Data Sources 3.2 Market Estimation Model 3.2.1 Assumptions Limitations4. Global Weight Loss Drugs Market: Overview 4.1 Key Trends 4.2 Pipeline Analysis 4.3 Patent Analysis 4.4 Regulatory Framework5. Global Weight Loss Drugs Market: Market Dynamics 5.1 Impact Analysis 5.2 Market Drivers 5.3 Market Restraints 5.4 Market Opportunities6. Global Weight Loss Drugs Market (by Type), ($Million) 6.1 Prescription Weight Loss Drugs 6.2 Over the Counter (OTC) Weight Loss Drugs7. Global Weight Loss Drugs Market (by Mechanism of Action) 7.1 Appetite Suppressants 7.2 Metabolic Boosters 7.3 Fat Absorption Inhibitors8. Global Weight Loss Drugs Market (by Route of Administration) 8.1 Oral 8.2 Injectable9. Global Weight Loss Drugs Market (by Distribution Channel) 9.1 Retail Pharmacies 9.2 Online Pharmacies10. Global Weight Loss Market (by Region), Value ($Million) 10.1 North America Weight Loss Drugs Market 10.1.1 Market Dynamics 10.1.2 Market Size and Forecast 10.1.2.1 U.S. 10.1.2.2 Canada 10.2 Europe Weight Loss Drugs Market 10.2.1 Market Dynamics 10.2.2 Market Sizing and Forecast 10.2.2.1 Germany 10.2.2.2 U.K. 10.2.2.3 France 10.2.2.4 Rest-of-Europe 10.3 Asia-Pacific Weight Loss Drugs Market 10.3.1 Market Dynamics 10.3.2 Market Size and Forecast 10.3.2.1 China 10.3.2.2 Japan 10.3.2.3 India 10.3.2.4 Rest-of Asia-Pacific 10.4 Rest-of-the-World Weight Loss Drugs Market 10.4.1 Market Dynamics 10.4.2 Market Size and Forecast11. Global Weight Loss Drugs Market: Competitive Landscape 11.1 Key Strategies and Development 11.1.1 New Offerings 11.1.2 Regulatory Approvals 11.1.3 Mergers and Acquisitions 11.1.4 Partnerships, Alliances, and Business Expansions 11.1.5 Funding Activities 11.2 Company Profiles 11.2.1 Company Overview 11.2.2 Product Portfolio/Offering 11.2.3 Key Competitors 11.2.4 Target Customers/End Users 11.2.5 Analyst ViewFor more information about this report visit https://www.researchandmarkets.com/r/svnc48</div> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre></pre> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWMxZTQ4YTYtNDNhOS00NTQ5LWE5NTMtMTVhZmZkZWQ4MGY5LTEwMjY3MzctMjAyNS0wMy0yNy1lbg==/tiny/Research-and-Markets.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YWMxZTQ4YTYtNDNhOS00NTQ5LWE5NTMtMTVhZmZkZWQ4MGY5LTEwMjY3MzctMjAyNS0wMy0yNy1lbg==/tiny/Research-and-Markets.png"/></div>

禮來

諾和諾德公司

全球減肥藥市場預計將在 2025 年至 2035 年間顯著增長，主要受肥胖率上升和醫學研究進展的推動，這些進展導致了更安全、更有效的藥物問世。像 semaglutide 和 liraglutide 這樣的處方藥因其臨牀療效而日益受到歡迎，但對副作用和高成本的擔憂可能會阻礙市場增長。北美預計將主導市場，得益於強大的醫療保健系統和高肥胖率。主要參與者包括諾和諾德、禮來和輝瑞

Weight Loss Drugs Market Global Report 2025-2035: Advances in Medical Research have Led to the Development of More Effective and Safer Weight Loss Medications with Less Negative Side-Effects

減肥藥物市場全球報告 2025-2035：醫學研究的進步已經導致開發出更有效且更安全的減肥藥物，並且負面副作用更少